Axa Pharmaceuticals joined forces with Suzhou University's affiliated First Hospital to focus on the clinical transformation of blood tumor research.

On July 3, Yasheng medicine (6855. HK), which is committed to developing innovative drugs in the treatment of cancer, hepatitis B and aging related diseases, announced that it had held a signing ceremony with the National Clinical Medical Research Center for hematological diseases.the two sides will jointly build the "Yasheng Research Institute of national blood system diseases clinical medicine research center", increase the research and clinical development in the field of blood tumor, and carry out comprehensive and deep-seated cooperation in the fields of basic cancer research, clinical treatment research, innovative drug research and development, innovative talent training, and key core technology platform cultivation.at the 2020 Suzhou biomedical development conference, the implementation plan for Building Suzhou biomedical industry landmark (2020-2030) was released.at the meeting, LAN Shaomin, member of the Standing Committee of Jiangsu Provincial Committee and Secretary of Suzhou municipal Party committee, pointed out that Suzhou should make full use of the strength of the whole city and pool the wisdom of all parties to jointly create a world-class biomedical industry landmark and become the "Chinese Medicine Valley" which is internationally famous, the most representative and competitive in China.speeding up the construction of local clinical research capacity and building a number of pharmaceutical landmark enterprises is one of the important contents.under this background, Yasheng pharmaceutical, which was one of the first batch of potential landmark enterprises in Suzhou, and the national clinical research center of hematological diseases, a key clinical research institution in Suzhou, actively explored.by giving full play to and combining their respective comprehensive resource advantages, the two sides will further enhance the local clinical research ability of Suzhou, accelerate the industrialization and transformation progress of original new drugs of landmark enterprises, and help the development of "China Medicine Valley" in Suzhou and benefit more patients.at the signing ceremony, the two sides signed a cooperation agreement on five clinical projects, including the mechanism and clinical research of apg-2575, a novel Bcl-2 inhibitor of AXA, in multiple myeloma, in Fahrenheit's macroglobulinemia, and in the clinical study of apg-2575 monotherapy and combination therapy in acute mixed phenotype leukemia.for this cooperation, Dr. Yang Dajun, chairman and CEO of AXA Pharmaceutical Co., Ltd., said, "we are very happy to reach a strategic cooperation with the national clinical research center of hematological diseases led by director Wu Depai to build the research Institute.the National Center for clinical medicine of hematological diseases has incomparable advantages in terms of academic level and clinical resources in the field of hematological tumors.and blood tumor has always been one of the important research and development directions of Yasheng pharmaceutical product pipeline, and a number of varieties under research of the company have shown great potential in the treatment of this disease.more importantly, Yasheng medicine and the National Center for clinical medicine of hematological diseases share one of the common goals, that is, "to solve the unmet clinical needs in the field of blood diseases", which is the starting point and the end point of the cooperation.we hope that our cooperation can give full play to the advantages of both sides, present the positive effect of hospital enterprise cooperation and collaborative innovation, and jointly promote the clinical development of innovative drugs related to blood tumor, and provide safer and effective treatment options for patients. Wu Depei, chairman of the hematology branch of the Chinese Medical Association and director of the Hematology Department of the First Affiliated Hospital of Jiangsu University, said, "the signing of the strategic cooperation project between the national clinical research center of Hematology Diseases and Yasheng pharmaceutical is of great significance to promote the development of the biomedical industry in Suzhou and the transformation research in the field of Hematology in China.we hope to give full play to the new advantages of the collaborative development of medicine, teaching, research and production, vigorously promote the innovation of clinical research and new drug research, actively explore the talent training mode adapting to the new situation, push the strategic cooperation of the two sides to a new height, add new bricks to the construction of national clinical medical research center for hematological diseases, and make greater contributions to the construction of healthy China and healthy Jiangsu."as one of the first batch of enterprises focusing on original new drug research and development in China, Yasheng pharmaceutical has formed a series of product distribution in the fields of tumor, hepatitis B and aging related diseases after 10 years of persistence. At present, eight class 1 new drugs have entered the clinical development stage, and more than 30 phase I / II clinical trials are being carried out in China, the United States and Australia.the company's core product, hqp1351, the third generation bcr-abl inhibitor for drug-resistant chronic myeloid leukemia, submitted its new drug application in mid June this year, which will become the company's first product on the market.it is particularly noteworthy that Yasheng medicine has made positive progress in the clinical development of blood tumor treatment. the company, including hqp1351, apg-2575 and apg-115, has carried out a number of clinical studies in China and the United States in the treatment of multiple hematological tumor indications such as chronic myeloid leukemia, chronic lymphocytic leukemia / small cell lymphoma, Fahrenheit's macroglobulinemia, acute myeloid leukemia, etc. End